Mercosur would benefit from single pharmacopoeia, says Brazilian regulator
This article was originally published in Scrip
Executive Summary
A single pharmacopeia would help the South American trade bloc Mercosur strengthen its pharmaceutical industry and reduce dependence on outside manufacturers, said ANVISA, Brazil's medicines regulator, last week at the country's annual pharmacopoeia meeting.